Aimmune Therapeutics Says Nestle Health Science to Make Additional Equity Investment of $200 Million
February 05 2020 - 8:55AM
Dow Jones News
By Michael Dabaie
Aimmune Therapeutics Inc. (AIMT) said Nestle Health Science will
make an additional equity investment in Aimmune of $200
million.
The biopharmaceutical company focused on food allergies said
that brings Nestle's total investment in Aimmune to date to $473
million.
The Nestle Health Science investment includes the purchase of 1
million shares of Aimmune common stock and 525,634 shares of
convertible preferred stock.
Upon closing of the equity investment, Aimmune will receive a
payment of $200 million in connection with Nestle Health Science's
purchase of 1 million newly issued shares at $31.97 per share.
Nestle Health Science's total investments in Aimmune will
correspond to ownership of 19.9% of Aimmune's outstanding common
stock and voting power, and 25.6% overall stake in the company's
fully-diluted capitalization.
The companies expect to close the equity investment on February
7.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
February 05, 2020 08:40 ET (13:40 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Nestle (PK) (USOTC:NSRGY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nestle (PK) (USOTC:NSRGY)
Historical Stock Chart
From Sep 2023 to Sep 2024
